nevirapine ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
antivirals 1904 129618-40-2

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • nevirapine hemihydrate
  • nevirapine
  • viramune
  • nevarapine
A potent, non-nucleoside reverse transcriptase inhibitor used in combination with nucleoside analogues for treatment of HIV INFECTIONS and AIDS.
  • Molecular weight: 266.30
  • Formula: C15H14N4O
  • CLOGP: 2.72
  • LIPINSKI: 0
  • HAC: 5
  • HDO: 1
  • TPSA: 58.12
  • ALOGS: -3.41
  • ROTB: 1

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.40 g O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 0.10 mg/mL Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 21.46 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 93 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 1.30 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 0.30 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.32 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 53 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
June 21, 1996 FDA BOEHRINGER INGELHEIM

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug resistance 712.65 30.25 220 8466 18769 50577669
Viral mutation identified 669.70 30.25 130 8556 1499 50594939
Exposure during pregnancy 625.84 30.25 336 8350 120679 50475759
Stillbirth 555.92 30.25 141 8545 5811 50590627
Virologic failure 552.68 30.25 110 8576 1454 50594984
Abortion spontaneous 515.59 30.25 212 8474 41560 50554878
Foetal exposure during pregnancy 372.03 30.25 149 8537 27210 50569228
Pregnancy 317.24 30.25 136 8550 29441 50566997
Pathogen resistance 291.56 30.25 84 8602 5605 50590833
Stevens-Johnson syndrome 236.35 30.25 101 8585 21651 50574787
Abortion induced 226.92 30.25 78 8608 9266 50587172
Caesarean section 222.22 30.25 88 8598 15551 50580887
Premature baby 198.70 30.25 85 8601 18252 50578186
Lipodystrophy acquired 198.45 30.25 46 8640 1283 50595155
Maternal exposure during pregnancy 183.66 30.25 178 8508 159600 50436838
Immune reconstitution inflammatory syndrome 181.81 30.25 58 8628 5458 50590980
Acquired gene mutation 125.32 30.25 29 8657 802 50595636
Portal hypertension 121.45 30.25 38 8648 3354 50593084
Viral load increased 120.63 30.25 30 8656 1133 50595305
Maternal drugs affecting foetus 114.02 30.25 40 8646 5037 50591401
Foetal death 95.47 30.25 40 8646 8140 50588298
Supernumerary nipple 93.55 30.25 15 8671 48 50596390
Rash maculo-papular 91.54 30.25 57 8629 26584 50569854
Acoustic stimulation tests abnormal 87.24 30.25 15 8671 81 50596357
Congenital naevus 83.52 30.25 16 8670 170 50596268
Blood HIV RNA increased 81.94 30.25 19 8667 530 50595908
Amniotic cavity infection 81.68 30.25 22 8664 1141 50595297
Postpartum sepsis 80.97 30.25 11 8675 4 50596434
Low set ears 77.57 30.25 16 8670 254 50596184
Premature delivery 77.20 30.25 49 8637 23614 50572824
CD4 lymphocytes decreased 74.07 30.25 21 8665 1318 50595120
Toxic epidermal necrolysis 69.80 30.25 44 8642 20948 50575490
Malaria 69.38 30.25 14 8672 198 50596240
Conjunctivalisation 69.04 30.25 9 8677 0 50596438
Mitochondrial toxicity 67.54 30.25 15 8671 343 50596095
Pain 62.44 30.25 12 8674 578891 50017547
Premature rupture of membranes 62.31 30.25 25 8661 4555 50591883
Hyperlactacidaemia 61.72 30.25 21 8665 2412 50594026
Drug ineffective 60.47 30.25 33 8653 819300 49777138
Hepatitis 60.21 30.25 47 8639 31406 50565032
Low birth weight baby 59.51 30.25 26 8660 5855 50590583
Pre-eclampsia 57.69 30.25 28 8658 8016 50588422
Immune reconstitution inflammatory syndrome associated tuberculosis 57.66 30.25 13 8673 319 50596119
Hemivertebra 57.32 30.25 11 8675 118 50596320
Premature separation of placenta 56.74 30.25 18 8668 1660 50594778
Foetal growth restriction 56.53 30.25 26 8660 6601 50589837
Premature labour 56.46 30.25 31 8655 11445 50584993
Live birth 56.07 30.25 35 8651 16373 50580065
Placental disorder 55.31 30.25 17 8669 1413 50595025
Hypertriglyceridaemia 54.67 30.25 24 8662 5467 50590971
Blood lactic acid increased 54.28 30.25 24 8662 5561 50590877
Uveal prolapse 53.70 30.25 7 8679 0 50596438
Eyelid scar 53.70 30.25 7 8679 0 50596438
Lactic acidosis 53.60 30.25 45 8641 33310 50563128
Hepatotoxicity 52.79 30.25 41 8645 27185 50569253
Hepatomegaly 52.67 30.25 29 8657 10764 50585674
Nephropathy toxic 51.79 30.25 26 8660 8003 50588435
Retinoblastoma 48.74 30.25 9 8677 77 50596361
Varices oesophageal 47.78 30.25 18 8668 2771 50593667
Eyelid oedema 47.75 30.25 26 8660 9440 50586998
Lipoatrophy 47.60 30.25 11 8675 302 50596136
Oligohydramnios 47.30 30.25 22 8664 5728 50590710
Congenital choroid plexus cyst 47.19 30.25 11 8675 314 50596124
Drug reaction with eosinophilia and systemic symptoms 47.01 30.25 39 8647 28385 50568053
Neonatal disorder 45.99 30.25 12 8674 550 50595888
Fat tissue increased 45.84 30.25 12 8674 557 50595881
Mitochondrial cytopathy 45.18 30.25 10 8676 225 50596213
Off label use 44.85 30.25 13 8673 474413 50122025
Pyrexia 43.94 30.25 154 8532 380049 50216389
Acute HIV infection 43.59 30.25 6 8680 3 50596435
Ulcerative keratitis 43.42 30.25 16 8670 2317 50594121
Anaemia 42.86 30.25 117 8569 252339 50344099
Neutropenia neonatal 42.57 30.25 8 8678 76 50596362
Alanine aminotransferase increased 42.02 30.25 63 8623 88296 50508142
Hydrops foetalis 41.36 30.25 10 8676 335 50596103
Ventricular septal defect 41.32 30.25 18 8668 4023 50592415
Normal newborn 41.20 30.25 21 8665 6670 50589768
Jaundice 41.10 30.25 35 8651 26394 50570044
Fatigue 40.89 30.25 37 8649 707564 49888874
Pulmonary tuberculosis 40.36 30.25 18 8668 4255 50592183
Developmental delay 40.14 30.25 13 8673 1281 50595157
Left ventricular dilatation 39.22 30.25 10 8676 418 50596020
Nodular regenerative hyperplasia 38.41 30.25 9 8677 263 50596175
Congenital anomaly 38.07 30.25 13 8673 1508 50594930
CD4 lymphocytes increased 38.05 30.25 8 8678 140 50596298
Astrocytoma malignant 37.71 30.25 6 8680 18 50596420
Portal vein thrombosis 36.90 30.25 14 8672 2198 50594240
Proteinuria 36.60 30.25 27 8659 16570 50579868
Atrial septal defect 36.44 30.25 19 8667 6322 50590116
Neural tube defect 35.97 30.25 8 8678 184 50596254
Fall 35.90 30.25 7 8679 334925 50261513
Gamma-glutamyltransferase increased 35.74 30.25 34 8652 29589 50566849
HIV antibody positive 34.41 30.25 5 8681 6 50596432
Hereditary optic atrophy 33.21 30.25 5 8681 9 50596429
Genotype drug resistance test positive 32.69 30.25 8 8678 282 50596156
Foetal distress syndrome 32.57 30.25 11 8675 1234 50595204
Porphyria non-acute 32.50 30.25 8 8678 289 50596149
Skin toxicity 32.28 30.25 15 8671 3898 50592540
Neonatal hepatomegaly 32.24 30.25 5 8681 12 50596426
Human immunodeficiency virus transmission 32.22 30.25 6 8680 54 50596384
Polydactyly 32.14 30.25 8 8678 303 50596135
Eosinophilia 31.69 30.25 26 8660 18626 50577812
Spinocerebellar disorder 31.42 30.25 5 8681 15 50596423
Breast disorder 30.87 30.25 12 8674 2010 50594428
Tuberculosis 30.69 30.25 20 8666 10063 50586375
Arthralgia 30.32 30.25 19 8667 438683 50157755

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Lipodystrophy acquired 741.27 18.97 180 10273 2914 29561160
Mitochondrial toxicity 581.13 18.97 141 10312 2270 29561804
Foetal exposure during pregnancy 512.25 18.97 246 10207 33621 29530453
Virologic failure 498.90 18.97 129 10324 2718 29561356
Eyelid ptosis 469.75 18.97 140 10313 5046 29559028
Viral mutation identified 403.36 18.97 106 10347 2382 29561692
Diplopia 328.39 18.97 137 10316 13381 29550693
Progressive external ophthalmoplegia 311.99 18.97 76 10377 1241 29562833
Drug resistance 264.46 18.97 136 10317 21404 29542670
Exposure during pregnancy 263.92 18.97 103 10350 8451 29555623
Dandy-Walker syndrome 226.53 18.97 40 10413 105 29563969
Pathogen resistance 219.92 18.97 89 10364 8027 29556047
Developmental delay 189.50 18.97 59 10394 2459 29561615
Premature baby 166.72 18.97 93 10360 17187 29546887
Pinealoblastoma 166.64 18.97 32 10421 151 29563923
Speech disorder developmental 161.82 18.97 49 10404 1858 29562216
Immune reconstitution inflammatory syndrome 149.71 18.97 67 10386 7735 29556339
Polydactyly 126.19 18.97 36 10417 1104 29562970
Volvulus 125.30 18.97 36 10417 1133 29562941
Stevens-Johnson syndrome 122.64 18.97 75 10378 16422 29547652
Trisomy 21 113.66 18.97 28 10425 479 29563595
Congenital central nervous system anomaly 106.42 18.97 26 10427 429 29563645
Ophthalmoplegia 100.19 18.97 33 10420 1649 29562425
Vanishing bile duct syndrome 90.21 18.97 24 10429 564 29563510
Brachydactyly 81.71 18.97 18 10435 183 29563891
Neurodevelopmental disorder 77.34 18.97 19 10434 321 29563753
Macrocephaly 73.22 18.97 19 10434 404 29563670
Blood lactic acid increased 72.36 18.97 37 10416 5729 29558345
Acquired gene mutation 72.20 18.97 24 10429 1234 29562840
Portal hypertension 67.05 18.97 30 10423 3456 29560618
Neonatal disorder 65.41 18.97 20 10433 783 29563291
Maternal drugs affecting foetus 63.88 18.97 30 10423 3863 29560211
Small for dates baby 63.14 18.97 29 10424 3550 29560524
Viral load increased 60.77 18.97 24 10429 2025 29562049
Hypertriglyceridaemia 60.73 18.97 36 10417 7439 29556635
Product residue present 59.10 18.97 25 10428 2514 29561560
Caesarean section 58.70 18.97 23 10430 1900 29562174
Lipoatrophy 56.63 18.97 16 10437 473 29563601
Osteonecrosis 56.33 18.97 43 10410 13476 29550598
Congenital neoplasm 55.63 18.97 10 10443 30 29564044
Off label use 53.26 18.97 20 10433 300780 29263294
Attention deficit hyperactivity disorder 52.17 18.97 22 10431 2195 29561879
Nodular regenerative hyperplasia 51.36 18.97 16 10437 667 29563407
Dyslipidaemia 48.74 18.97 29 10424 6032 29558042
Conjunctivalisation 48.64 18.97 7 10446 0 29564074
Drug ineffective 48.30 18.97 35 10418 363135 29200939
Low birth weight baby 46.42 18.97 29 10424 6579 29557495
Fall 45.14 18.97 5 10448 177173 29386901
Blood HIV RNA increased 45.00 18.97 16 10437 1008 29563066
Mitochondrial myopathy 44.38 18.97 11 10442 193 29563881
Laryngomalacia 44.36 18.97 12 10441 301 29563773
Nephropathy toxic 44.34 18.97 34 10419 10722 29553352
Hepatotoxicity 43.96 18.97 42 10411 17825 29546249
Toxic epidermal necrolysis 43.39 18.97 42 10411 18111 29545963
Fanconi syndrome acquired 42.42 18.97 18 10435 1824 29562250
Gene mutation 41.00 18.97 15 10438 1026 29563048
HIV peripheral neuropathy 37.19 18.97 7 10446 29 29564045
Cerebellar hypoplasia 36.61 18.97 6 10447 8 29564066
Atrioventricular septal defect 36.31 18.97 9 10444 158 29563916
Congenital umbilical hernia 35.81 18.97 10 10443 283 29563791
Speech disorder 34.41 18.97 42 10411 23474 29540600
Treatment failure 34.39 18.97 53 10400 36886 29527188
Osteoporotic fracture 34.34 18.97 13 10440 978 29563096
Hepatitis 33.50 18.97 39 10414 20744 29543330
Bone metabolism disorder 32.81 18.97 9 10444 238 29563836
Hypotension 32.57 18.97 14 10439 194340 29369734
Human immunodeficiency virus transmission 31.29 18.97 6 10447 28 29564046
Meningitis cryptococcal 30.84 18.97 15 10438 2085 29561989
Pneumonia 30.79 18.97 41 10412 320131 29243943
Dysphagia 30.67 18.97 63 10390 54863 29509211
Varices oesophageal 30.49 18.97 17 10436 3129 29560945
Gamma-glutamyltransferase increased 30.15 18.97 42 10411 26695 29537379
Death neonatal 30.00 18.97 9 10444 330 29563744
Hepatomegaly 28.99 18.97 25 10428 9292 29554782
Rash 28.86 18.97 138 10315 189681 29374393
HIV infection 28.73 18.97 12 10441 1169 29562905
Hepatic cirrhosis 28.26 18.97 30 10423 14414 29549660
Tuberculosis 28.03 18.97 22 10431 7174 29556900
Osteoporosis 27.79 18.97 26 10427 10743 29553331
Low set ears 27.74 18.97 9 10444 428 29563646
Congenital anomaly 27.37 18.97 12 10441 1316 29562758
Constipation 27.17 18.97 4 10449 114156 29449918
Multiple-drug resistance 27.10 18.97 17 10436 3883 29560191
Pain 26.19 18.97 14 10439 171418 29392656
Alanine aminotransferase increased 26.01 18.97 69 10384 70875 29493199
Hepatic steatosis 25.69 18.97 29 10424 14917 29549157
Protrusion tongue 25.60 18.97 7 10446 183 29563891
Syphilis 25.57 18.97 8 10445 338 29563736
Blindness 25.37 18.97 26 10427 11997 29552077
Kaposi's sarcoma 25.22 18.97 10 10443 852 29563222
Congenital nose malformation 25.17 18.97 7 10446 195 29563879
Anaemia macrocytic 24.92 18.97 14 10439 2614 29561460
Meconium ileus 24.88 18.97 5 10448 31 29564043
Liver function test abnormal 24.84 18.97 40 10413 28878 29535196
Hyperlactacidaemia 24.67 18.97 14 10439 2664 29561410
Synostosis 24.28 18.97 6 10447 104 29563970
Oral candidiasis 24.11 18.97 24 10429 10698 29553376
Aspartate aminotransferase increased 23.86 18.97 60 10393 59665 29504409
Aplasia cutis congenita 23.51 18.97 6 10447 119 29563955
Optic nerve cupping 23.45 18.97 5 10448 43 29564031
Subchondral insufficiency fracture 23.40 18.97 4 10449 8 29564066
Loss of anatomical alignment after fracture reduction 23.40 18.97 4 10449 8 29564066
Molluscum contagiosum 23.19 18.97 7 10446 262 29563812
Retinoblastoma 22.79 18.97 4 10449 10 29564064
Umbilical hernia 22.78 18.97 15 10438 3720 29560354
Proteinuria 22.75 18.97 28 10425 15776 29548298
Anaemia neonatal 22.70 18.97 7 10446 282 29563792
Fracture malunion 22.51 18.97 4 10449 11 29564063
Hepatitis cholestatic 22.48 18.97 19 10434 6874 29557200
Glycosuria 22.34 18.97 10 10443 1152 29562922
Ataxia 21.69 18.97 24 10429 12079 29551995
Hypercholesterolaemia 21.67 18.97 19 10434 7219 29556855
Suspected COVID-19 21.63 18.97 8 10445 564 29563510
Chronic hepatitis C 21.48 18.97 7 10446 338 29563736
Acute HIV infection 21.43 18.97 5 10448 67 29564007
Blood insulin increased 21.20 18.97 7 10446 352 29563722
Hepatic failure 21.05 18.97 39 10414 31473 29532601
Lactic acidosis 20.92 18.97 38 10415 30209 29533865
Pyrexia 20.88 18.97 173 10280 287449 29276625
Hyperplasia adrenal 20.85 18.97 3 10450 0 29564074
Pulmonary tuberculosis 20.82 18.97 15 10438 4300 29559774
Primary syphilis 20.80 18.97 4 10449 19 29564055
Embolism venous 20.79 18.97 10 10443 1356 29562718
Elbow synostosis 20.63 18.97 4 10449 20 29564054
Dyspnoea 20.62 18.97 54 10399 326678 29237396
Febrile neutropenia 20.58 18.97 7 10446 112233 29451841
Neutropenia neonatal 20.55 18.97 8 10445 649 29563425
CD4 lymphocytes increased 20.16 18.97 6 10447 214 29563860
Congenital tuberculosis 20.02 18.97 4 10449 24 29564050
Congenital cytomegalovirus infection 19.74 18.97 4 10449 26 29564048
Portal vein thrombosis 19.49 18.97 13 10440 3296 29560778
Fanconi syndrome 19.31 18.97 10 10443 1588 29562486

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Lipodystrophy acquired 985.85 19.19 216 13203 3811 64481502
Virologic failure 771.43 19.19 172 13247 3294 64482019
Mitochondrial toxicity 728.51 19.19 157 13262 2549 64482764
Viral mutation identified 679.05 19.19 154 13265 3192 64482121
Drug resistance 628.63 19.19 246 13173 34856 64450457
Eyelid ptosis 454.51 19.19 139 13280 9386 64475927
Abortion spontaneous 445.59 19.19 175 13244 24968 64460345
Stillbirth 414.22 19.19 105 13314 3528 64481785
Exposure during pregnancy 369.53 19.19 219 13200 77456 64407857
Progressive external ophthalmoplegia 357.07 19.19 77 13342 1250 64484063
Immune reconstitution inflammatory syndrome 331.72 19.19 117 13302 12353 64472960
Diplopia 308.01 19.19 137 13282 26628 64458685
Pathogen resistance 304.58 19.19 110 13309 12433 64472880
Stevens-Johnson syndrome 302.76 19.19 146 13273 34103 64451210
Pregnancy 221.54 19.19 101 13318 20764 64464549
Abortion induced 216.96 19.19 72 13347 6316 64478997
Acquired gene mutation 204.79 19.19 53 13366 1933 64483380
Portal hypertension 187.12 19.19 64 13355 6155 64479158
Caesarean section 153.41 19.19 65 13354 11209 64474104
Viral load increased 152.08 19.19 44 13375 2443 64482870
Maternal drugs affecting foetus 123.25 19.19 34 13385 1586 64483727
Maternal exposure during pregnancy 122.92 19.19 124 13295 95760 64389553
Conjunctivalisation 112.52 19.19 16 13403 9 64485304
Foetal exposure during pregnancy 111.39 19.19 40 13379 4436 64480877
Toxic epidermal necrolysis 101.04 19.19 74 13345 37092 64448221
Nephropathy toxic 98.03 19.19 55 13364 17459 64467854
Ophthalmoplegia 97.93 19.19 32 13387 2670 64482643
Vanishing bile duct syndrome 93.46 19.19 26 13393 1251 64484062
Lipoatrophy 85.26 19.19 21 13398 624 64484689
Hepatotoxicity 81.25 19.19 67 13352 39895 64445418
Product residue present 73.32 19.19 27 13392 3215 64482098
Blood HIV RNA increased 72.18 19.19 22 13397 1462 64483851
Premature delivery 71.83 19.19 46 13373 18543 64466770
Postpartum sepsis 71.42 19.19 10 13409 4 64485309
Pulmonary tuberculosis 70.39 19.19 33 13386 7211 64478102
Nodular regenerative hyperplasia 69.61 19.19 19 13400 851 64484462
Dyslipidaemia 68.52 19.19 35 13384 9207 64476106
Proteinuria 68.19 19.19 52 13367 27671 64457642
Ulcerative keratitis 67.13 19.19 25 13394 3072 64482241
Hepatitis 65.89 19.19 63 13356 45519 64439794
Fat tissue increased 65.55 19.19 18 13401 825 64484488
CD4 lymphocytes decreased 65.28 19.19 23 13396 2412 64482901
Retinoblastoma 65.06 19.19 12 13407 82 64485231
Hepatomegaly 63.31 19.19 41 13378 16841 64468472
Varices oesophageal 61.32 19.19 27 13392 5103 64480210
Tuberculosis 59.84 19.19 36 13383 13002 64472311
Blood lactic acid increased 59.11 19.19 33 13386 10368 64474945
Pain 58.75 19.19 21 13398 553490 63931823
Off label use 57.67 19.19 30 13389 632776 63852537
Fall 55.34 19.19 10 13409 416816 64068497
Premature baby 55.16 19.19 22 13397 3250 64482063
Gamma-glutamyltransferase increased 53.60 19.19 58 13361 48452 64436861
Drug ineffective 53.34 19.19 58 13361 840189 63645124
Hepatic cirrhosis 53.25 19.19 44 13375 26254 64459059
Immune reconstitution inflammatory syndrome associated tuberculosis 53.20 19.19 15 13404 758 64484555
Uveal prolapse 52.35 19.19 7 13412 0 64485313
Eyelid scar 52.35 19.19 7 13412 0 64485313
Rash maculo-papular 51.56 19.19 56 13363 46970 64438343
Foetal death 51.48 19.19 25 13394 5905 64479408
Alanine aminotransferase increased 50.69 19.19 98 13321 138933 64346380
Pre-eclampsia 50.30 19.19 25 13394 6206 64479107
Pyrexia 50.10 19.19 239 13180 558405 63926908
Meningitis cryptococcal 49.92 19.19 20 13399 2989 64482324
Acute HIV infection 49.25 19.19 9 13410 58 64485255
Osteonecrosis 48.53 19.19 43 13376 28186 64457127
Malaria 48.51 19.19 12 13407 363 64484950
Mitochondrial cytopathy 47.95 19.19 12 13407 381 64484932
Placental disorder 47.06 19.19 14 13405 856 64484457
Mitochondrial myopathy 46.37 19.19 11 13408 278 64485035
Glycosuria 45.90 19.19 17 13402 2057 64483256
Oligohydramnios 45.79 19.19 19 13400 3105 64482208
Jaundice 45.06 19.19 53 13366 48459 64436854
Blindness 44.91 19.19 37 13382 21982 64463331
Dandy-Walker syndrome 44.71 19.19 8 13411 45 64485268
Fanconi syndrome acquired 43.34 19.19 17 13402 2404 64482909
Portal vein thrombosis 43.20 19.19 21 13398 4970 64480343
Pinealoblastoma 42.15 19.19 8 13411 65 64485248
Anaemia 41.41 19.19 172 13247 378508 64106805
HIV infection 41.20 19.19 13 13406 969 64484344
Normal newborn 40.85 19.19 21 13398 5596 64479717
Multiple-drug resistance 40.73 19.19 22 13397 6480 64478833
Hypercholesterolaemia 40.38 19.19 30 13389 15343 64469970
Drug reaction with eosinophilia and systemic symptoms 40.35 19.19 53 13366 54164 64431149
HIV peripheral neuropathy 39.81 19.19 7 13412 35 64485278
Eyelid oedema 39.24 19.19 27 13392 12252 64473061
Hepatic failure 37.94 19.19 52 13367 55342 64429971
Congenital anomaly 37.19 19.19 9 13410 248 64485065
Live birth 36.67 19.19 25 13394 11179 64474134
Genotype drug resistance test positive 36.36 19.19 12 13407 1032 64484281
Aspartate aminotransferase increased 36.02 19.19 78 13341 119710 64365603
Hepatic steatosis 35.88 19.19 38 13381 30969 64454344
Premature labour 34.86 19.19 21 13398 7599 64477714
Hypertriglyceridaemia 34.31 19.19 24 13395 11181 64474132
Lactic acidosis 33.82 19.19 52 13367 61358 64423955
Joint swelling 33.76 19.19 3 13416 215379 64269934
Neutropenia neonatal 33.65 19.19 6 13413 33 64485280
Completed suicide 32.93 19.19 4 13415 224410 64260903
Dysphagia 32.63 19.19 70 13349 106742 64378571
Bone metabolism disorder 32.57 19.19 9 13410 422 64484891
Hyperlactacidaemia 32.05 19.19 17 13402 4827 64480486
Hypotension 31.85 19.19 20 13399 380954 64104359
Treatment noncompliance 31.57 19.19 42 13377 43440 64441873
Amniotic cavity infection 31.45 19.19 10 13409 764 64484549
Fatigue 30.87 19.19 69 13350 748661 63736652
Speech disorder developmental 30.26 19.19 9 13410 550 64484763
Conjunctival hyperaemia 29.58 19.19 15 13404 3884 64481429
Placental insufficiency 28.74 19.19 10 13409 1010 64484303
Drug-induced liver injury 28.60 19.19 42 13377 47601 64437712
Developmental delay 28.58 19.19 10 13409 1027 64484286
Anaemia neonatal 28.44 19.19 5 13414 25 64485288
Astrocytoma malignant 28.27 19.19 5 13414 26 64485287
Hepatitis cholestatic 28.14 19.19 22 13397 12133 64473180
Osteoporosis 28.05 19.19 39 13380 42041 64443272
Nasopharyngitis 27.56 19.19 4 13415 196069 64289244
Molluscum contagiosum 27.54 19.19 8 13411 450 64484863
Hereditary optic atrophy 27.39 19.19 5 13414 32 64485281
Hyperplasia adrenal 27.39 19.19 5 13414 32 64485281
Hepatic cytolysis 27.39 19.19 23 13396 14026 64471287
Lipase increased 26.89 19.19 23 13396 14379 64470934
Death neonatal 26.53 19.19 5 13414 39 64485274
Toxoplasmosis 26.45 19.19 12 13407 2432 64482881
Product use in unapproved indication 26.27 19.19 3 13416 176615 64308698
Rash 25.60 19.19 173 13246 458376 64026937
Loss of anatomical alignment after fracture reduction 25.52 19.19 4 13415 8 64485305
Blood pressure increased 25.49 19.19 3 13416 172549 64312764
Optic nerve cupping 25.32 19.19 5 13414 51 64485262
Borderline leprosy 25.20 19.19 4 13415 9 64485304
Brachydactyly 24.90 19.19 4 13415 10 64485303
Osteoporotic fracture 24.86 19.19 13 13406 3585 64481728
Symblepharon 24.53 19.19 6 13413 173 64485140
Meningitis tuberculous 24.19 19.19 9 13410 1102 64484211
Premature separation of placenta 23.94 19.19 9 13410 1135 64484178
Constipation 23.76 19.19 9 13410 229328 64255985
Congestive hepatopathy 23.65 19.19 13 13406 3960 64481353
Lymphadenopathy 23.58 19.19 38 13381 46648 64438665
Pneumonia 23.49 19.19 51 13368 559525 63925788
Syphilis 22.88 19.19 7 13412 471 64484842
Abdominal discomfort 22.84 19.19 5 13414 182317 64302996
Splenomegaly 22.55 19.19 23 13396 17938 64467375
Dyspnoea 22.30 19.19 76 13343 718598 63766715
Peripheral swelling 22.01 19.19 8 13411 209145 64276168
Chronic hepatitis C 22 19.19 7 13412 536 64484777
Left ventricular dilatation 21.96 19.19 8 13411 924 64484389
Disseminated tuberculosis 21.90 19.19 12 13407 3633 64481680
Febrile neutropenia 21.85 19.19 6 13413 187651 64297662
Gene mutation 21.83 19.19 10 13409 2072 64483241
Strabismus 21.58 19.19 10 13409 2127 64483186
Transaminases increased 20.77 19.19 35 13384 44559 64440754
Secondary syphilis 20.71 19.19 4 13415 36 64485277
Ascites 20.51 19.19 42 13377 61959 64423354
Sinusitis 20.45 19.19 3 13416 145925 64339388
Syncope 20.41 19.19 4 13415 157631 64327682
Kwashiorkor 20.36 19.19 3 13416 3 64485310
Portal hypertensive gastropathy 20.17 19.19 8 13411 1164 64484149
Fanconi syndrome 20.08 19.19 10 13409 2491 64482822
Congenital retinoblastoma 19.89 19.19 3 13416 4 64485309
Kaposi's sarcoma 19.79 19.19 7 13412 742 64484571
Cardiac arrest 19.76 19.19 4 13415 154060 64331253
Back pain 19.72 19.19 14 13405 250157 64235156
Embolism venous 19.58 19.19 11 13408 3496 64481817
Urinary tract infection 19.55 19.19 12 13407 231584 64253729
Liver function test abnormal 19.37 19.19 40 13379 59361 64425952

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC J05AG01 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIVIRALS FOR SYSTEMIC USE
DIRECT ACTING ANTIVIRALS
Non-nucleoside reverse transcriptase inhibitors
ATC J05AR05 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIVIRALS FOR SYSTEMIC USE
DIRECT ACTING ANTIVIRALS
Antivirals for treatment of HIV infections, combinations
ATC J05AR07 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIVIRALS FOR SYSTEMIC USE
DIRECT ACTING ANTIVIRALS
Antivirals for treatment of HIV infections, combinations
FDA MoA N0000009948 Non-Nucleoside Reverse Transcriptase Inhibitors
FDA EXT N0000175460 Non-Nucleoside Analog
FDA EPC N0000175463 Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor
FDA MoA N0000187064 Cytochrome P450 2B6 Inducers
FDA MoA N0000190118 Cytochrome P450 3A Inducers
CHEBI has role CHEBI:36044 antiviral drugs
CHEBI has role CHEBI:53756 reverse transcriptase inhibitors
MeSH PA D019380 Anti-HIV Agents
MeSH PA D000890 Anti-Infective Agents
MeSH PA D044966 Anti-Retroviral Agents
MeSH PA D000998 Antiviral Agents
MeSH PA D065701 Cytochrome P-450 CYP3A Inducers
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D065606 Metabolic Side Effects of Drugs and Substances
MeSH PA D019384 Nucleic Acid Synthesis Inhibitors
MeSH PA D018894 Reverse Transcriptase Inhibitors

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Human immunodeficiency virus infection indication 86406008 DOID:526
Lyell's toxic epidermal necrolysis, subepidermal type contraindication 23067006
Viral hepatitis C contraindication 50711007 DOID:1883
Acute nephropathy contraindication 58574008
Hepatic failure contraindication 59927004
Chronic type B viral hepatitis contraindication 61977001
Stevens-Johnson syndrome contraindication 73442001 DOID:0050426
Chronic hepatitis C contraindication 128302006
Liver function tests abnormal contraindication 166603001
Disease of liver contraindication 235856003 DOID:409
Drug-induced hepatitis contraindication 235876009
Rhabdomyolysis contraindication 240131006
Eruption of skin contraindication 271807003 DOID:0050486
Breastfeeding (mother) contraindication 413712001
Prevention of HIV Infection after Exposure contraindication




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 9.01 acidic
pKa2 2.45 Basic
pKa3 1.74 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
400MG VIRAMUNE XR BOEHRINGER INGELHEIM N201152 March 25, 2011 RX TABLET, EXTENDED RELEASE ORAL 8460704 March 12, 2029 TREATMENT OF HIV-1 BY ONCE DAILY ADMINISTRATION

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Reverse transcriptase/RNaseH Enzyme INHIBITOR Ki 6.40 CHEMBL CHEMBL
Gag-Pol polyprotein Polyprotein IC50 7.10 WOMBAT-PK
Pol polyprotein Enzyme IC50 7 CHEMBL
Reverse transcriptase Enzyme IC50 6.30 CHEMBL
Reverse transcriptase protein Unclassified Ki 5.40 CHEMBL

External reference:

IDSource
4020991 VUID
N0000148461 NUI
D00435 KEGG_DRUG
220988-26-1 SECONDARY_CAS_RN
4020991 VANDF
C0132326 UMLSCUI
CHEBI:63613 CHEBI
NEV PDB_CHEM_ID
CHEMBL57 ChEMBL_ID
DB00238 DRUGBANK_ID
D019829 MESH_DESCRIPTOR_UI
4463 PUBCHEM_CID
6815 INN_ID
99DK7FVK1H UNII
224890 RXNORM
175112 MMSL
5168 MMSL
6060 MMSL
d04029 MMSL
006062 NDDF
108704001 SNOMEDCT_US
386898005 SNOMEDCT_US
725663003 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Nevirapine HUMAN PRESCRIPTION DRUG LABEL 1 0378-4050 TABLET 200 mg ORAL ANDA 29 sections
Nevirapine HUMAN PRESCRIPTION DRUG LABEL 1 0378-4890 TABLET, EXTENDED RELEASE 400 mg ORAL ANDA 29 sections
Nevirapine HUMAN PRESCRIPTION DRUG LABEL 1 0378-6950 TABLET, EXTENDED RELEASE 100 mg ORAL ANDA 29 sections
Viramune HUMAN PRESCRIPTION DRUG LABEL 1 0597-0046 TABLET 200 mg ORAL NDA 27 sections
Viramune HUMAN PRESCRIPTION DRUG LABEL 1 0597-0047 SUSPENSION 50 mg ORAL NDA 27 sections
Viramune HUMAN PRESCRIPTION DRUG LABEL 1 0597-0123 TABLET, EXTENDED RELEASE 400 mg ORAL NDA 28 sections
Nevirapine HUMAN PRESCRIPTION DRUG LABEL 1 0781-5893 TABLET, EXTENDED RELEASE 400 mg ORAL ANDA 29 sections
Nevirapine Human Prescription Drug Label 1 31722-505 TABLET 200 mg ORAL ANDA 26 sections
Nevirapine Human Prescription Drug Label 1 33342-004 TABLET 200 mg ORAL ANDA 28 sections
NEVIRAPINE Human Prescription Drug Label 1 33342-238 TABLET, EXTENDED RELEASE 400 mg ORAL ANDA 29 sections
NEVIRAPINE HUMAN PRESCRIPTION DRUG LABEL 1 42571-131 TABLET 200 mg ORAL ANDA 27 sections
nevirapine HUMAN PRESCRIPTION DRUG LABEL 1 53104-0166 TABLET 200 mg ORAL ANDA 26 sections
Nevirapine HUMAN PRESCRIPTION DRUG LABEL 1 53808-0680 TABLET 200 mg ORAL ANDA 29 sections
Viramune HUMAN PRESCRIPTION DRUG LABEL 1 53808-0808 TABLET 200 mg ORAL NDA 31 sections
nevirapine HUMAN PRESCRIPTION DRUG LABEL 1 53808-1069 TABLET 200 mg ORAL ANDA 28 sections
Viramune HUMAN PRESCRIPTION DRUG LABEL 1 54868-6370 TABLET, EXTENDED RELEASE 400 mg ORAL NDA 29 sections
Nevirapine HUMAN PRESCRIPTION DRUG LABEL 1 61442-470 TABLET, COATED 200 mg ORAL ANDA 29 sections
Nevirapine HUMAN PRESCRIPTION DRUG LABEL 1 64380-709 TABLET 200 mg ORAL ANDA 28 sections
Nevirapine HUMAN PRESCRIPTION DRUG LABEL 1 65162-209 TABLET 200 mg ORAL ANDA 27 sections
Nevirapine Human Prescription Drug Label 1 65862-027 TABLET 200 mg ORAL ANDA 26 sections
Nevirapine Human Prescription Drug Label 1 65862-057 SUSPENSION 50 mg ORAL ANDA 28 sections
NEVIRAPINE Human Prescription Drug Label 1 65862-932 TABLET, EXTENDED RELEASE 100 mg ORAL ANDA 28 sections
NEVIRAPINE Human Prescription Drug Label 1 65862-933 TABLET, EXTENDED RELEASE 400 mg ORAL ANDA 28 sections
nevirapine HUMAN PRESCRIPTION DRUG LABEL 1 69097-233 SUSPENSION 50 mg ORAL ANDA 25 sections